Immunic Q3FY26 Results: EPS of $(0.99) misses estimate, loss narrows 25% YoY

Immunic Inc reported a Q3FY26 EPS loss of $(0.99), missing estimates by $(0.03) but narrowing losses by 25% YoY. Operating expenses rose 65% to $42.3M, with R&D and G&A costs increasing. The company expects Phase 3 ENSURE trial data in December 2026 and has $132M in cash to fund operations into late 2027.

Original reporting
Published Nov 13, 2026, 12:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2026, 7:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Immunic Q3FY26 Results: EPS of $(0.99) misses estimate, loss narrows 25% YoY — source image
Decision brief

The 30-second read

Med
01

Why it matters

The earnings miss by $0.03 per share may trigger short‑term price pressure, but the cash position and upcoming data could create volatility ahead of the December readout.

02

Market read

First‑report earnings release for a micro‑cap biotech; modest trading relevance with potential volatility around upcoming trial data.

03

What to watch

The significant share dilution from the February private placement masks the loss expansion; analysts may under‑weight the impact of the larger cash balance.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

Immunic Inc., a clinical‑stage biotech developing vidofludimus calcium for multiple sclerosis, released its Q3 FY2026 results, highlighting a narrowed loss per share and upcoming Phase‑3 trial readouts.

Market effects

Biotech sector may see modest pressure as a micro‑cap reports a loss miss but narrows EPS; peers could be impacted by upcoming Phase‑3 data expectations.

Limited to U.S. and Canadian biotech investors; no broader regional effect.

Low global relevance; primarily relevant to niche biotech investors.

Counterpoint

Despite the EPS miss, the expanded cash runway and upcoming pivotal trial data could support a short‑term bounce if investors focus on cash sufficiency.

Key entities

  • Immunic Inc.

    Biotech firm reporting Q3 FY2026 results and Phase‑3 trial timeline.

Related articles

$IMUXMedAI 8/10

Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

IMMUNIC, INC. (IMUX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update – Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 – – Initiatio

Med

Immunic Releases Q3 2026 Financial Results

Immunic Inc. reported a narrower Q3 2026 loss of $0.99 per share, down 25% from the prior year. The biotech company's net loss was $42.3M, attributed to R&D investments. Analysts remain bullish, with 9 buy and 1 hold rating. The company is developing therapies for chronic inflammatory and autoimmune diseases.

$IMUXMed

Immunic 3Q 2026: EPS ($0.99) — 10-Q Summary

Immunic reported a net loss of $42.3M, up 65% YoY, with operating expenses rising 67%. R&D costs increased 20%, while G&A expenses surged 225% due to personnel costs. Top-line data from Phase 3 trials is expected in December 2026. According to the company, Phase 3 progressive MS trial initiation is ongoing, with first-patient-enrolled expected in the first half of 2027.

$IMUXHigh

Immunic shares fall 5% on third quarter earnings miss

Immunic Inc. (IMUX) reported a Q3 loss of $0.99 per share, missing estimates by $0.05. Shares fell 5.44% premarket. Net loss was $42.3M, up from $25.6M last year, due to higher operating expenses. The company expects top-line data from ENSURE-1 and ENSURE-2 trials in December 2026. Cash reserves are $132.0M, expected to last into late 2027.

$IMUXMedAI 8/10

EQS-News: Immunic AG: Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

Immunic (IMUX) presented new clinical, biomarker, and preclinical data for vidofludimus calcium at MSToronto2026. Data showed durability of disability outcomes, neuroprotective effects, and reduced EBV-specific T-cell signatures. The company plans to initiate a Phase 3 program in progressive MS and expects top-line results from Phase 3 ENSURE trials by year-end 2026.